CompletedNot Applicable

Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study.

Colombia428 participantsStarted 2021-12-12

Plain-language summary

Purpose: To determine the impact of SARS-CoV-2 infection and immunization on ovarian response to controlled ovarian stimulation (COS) and embryo development after in vitro fertilization (IVF) Methods: A retrospective multicentric cohort study of 427 oocyte donors was conducted between January 1st, 2018 and September 18th, 2022. Patients who recovered from SARS-CoV-2 infection, vaccinated or non-exposed were included. Demographic, cycle characteristics, and laboratory outcomes were compared.

Who can participate

Age range18 Years – 32 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion * Age: 18 - 32 Years * Body Mass Index between 18 and 26 * AFC: Antral follicular count over 15 in total. * AMH: Anti-Mullerian hormone over 2.5 * Signed consents. * Covid vaccines and infection information (for case group). Exclusion: * Egg donors with incomplete information of days of stimulation, average dose of gonadotropins, the number of retrieved oocytes, mature oocytes, fertilised oocytes and top-quality embryos obtained. * Familial genetic disorders. * Menstrual cycle disorders. * Polycystic ovary syndrome.

What they're measuring

MII mature oocytes after retrieval

Timeframe: 2018 to 2022

Fertilization rate

Timeframe: 2018 to 2022

Blastocyst rate formation

Timeframe: 2018 to 2022

Trial details

NCT IDNCT05562479

SponsorNovafem

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-15

View on ClinicalTrials.gov More Ovarian Reserve trials